PE20181349A1 - Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador - Google Patents
Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimuladorInfo
- Publication number
- PE20181349A1 PE20181349A1 PE2018000513A PE2018000513A PE20181349A1 PE 20181349 A1 PE20181349 A1 PE 20181349A1 PE 2018000513 A PE2018000513 A PE 2018000513A PE 2018000513 A PE2018000513 A PE 2018000513A PE 20181349 A1 PE20181349 A1 PE 20181349A1
- Authority
- PE
- Peru
- Prior art keywords
- fnt
- tetravalence
- stimulating
- receiver
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Referido a moleculas biespecificas de union a antigeno, que comprende: (a) cuatro fracciones capaces de union especifica a un receptor de la familia de receptores de FNT coestimuladores, (b) por lo menos una fraccion capaz de union especifica a un antigeno de la celula diana, y (c) un dominio Fc compuesto de una primera y una segunda subunidades capaces de una asociacion estable; estas moleculas estimulan la respuesta y dan soporte a la supervivencia de celulas T. Tambien se refiere a metodos para producir dichas moleculas y a metodos de utilizacion de las mismas en el tratamiento de infecciones y cancer
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15188809 | 2015-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20181349A1 true PE20181349A1 (es) | 2018-08-22 |
Family
ID=54292631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018000513A PE20181349A1 (es) | 2015-10-07 | 2016-09-29 | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador |
Country Status (22)
Country | Link |
---|---|
US (3) | US20170247467A1 (es) |
EP (1) | EP3359568B1 (es) |
JP (1) | JP7074665B2 (es) |
KR (1) | KR20180054877A (es) |
CN (1) | CN108271377B (es) |
AR (1) | AR106574A1 (es) |
AU (1) | AU2016334623A1 (es) |
BR (1) | BR112018002128A2 (es) |
CA (1) | CA2992900A1 (es) |
CL (1) | CL2018000461A1 (es) |
CO (1) | CO2018000967A2 (es) |
CR (1) | CR20180171A (es) |
HK (1) | HK1257738A1 (es) |
IL (1) | IL257128A (es) |
MA (1) | MA45640A (es) |
MX (1) | MX2018004157A (es) |
MY (1) | MY193013A (es) |
PE (1) | PE20181349A1 (es) |
PH (1) | PH12018500766A1 (es) |
RU (1) | RU2018116402A (es) |
TW (1) | TW201726722A (es) |
WO (1) | WO2017060144A1 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
CN103502271B (zh) | 2011-02-28 | 2016-10-26 | 霍夫曼-拉罗奇有限公司 | 抗原结合蛋白 |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
JP6422956B2 (ja) * | 2013-10-11 | 2018-11-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性ドメイン交換共通可変軽鎖抗体 |
KR102588377B1 (ko) | 2014-11-14 | 2023-10-12 | 에프. 호프만-라 로슈 아게 | Tnf 계열 리간드 삼량체를 포함하는 항원 결합 분자 |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
CN114751989A (zh) | 2015-03-31 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
AU2016329120B2 (en) | 2015-10-02 | 2023-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for a costimulatory TNF receptor |
WO2017083525A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
CN109071613A (zh) | 2016-05-11 | 2018-12-21 | 通用电气医疗集团生物工艺研发股份公司 | 分离基质 |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
EA201990578A1 (ru) * | 2016-09-23 | 2019-10-31 | Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой | |
TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
ES2847973T3 (es) | 2016-12-20 | 2021-08-04 | Hoffmann La Roche | Politerapia de anticuerpos biespecíficos anti-CD20/anti-CD3 y agonistas de 4-1BB (CD137) |
MA47200A (fr) * | 2017-01-03 | 2019-11-13 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
WO2018127710A1 (en) | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
CA3050085A1 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
WO2018178055A1 (en) * | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
JP7205995B2 (ja) * | 2017-03-29 | 2023-01-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激性tnf受容体に対する二重特異性抗原結合分子 |
ES2928718T3 (es) | 2017-04-03 | 2022-11-22 | Hoffmann La Roche | Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15 |
KR102346336B1 (ko) | 2017-04-05 | 2022-01-04 | 에프. 호프만-라 로슈 아게 | Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체 |
MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
KR101886387B1 (ko) * | 2017-06-09 | 2018-08-09 | (주)젠아트 | 고토크의 순간 가속이 가능한 회전 장치 |
SG10201913144TA (en) | 2017-07-11 | 2020-03-30 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
AU2018309339A1 (en) | 2017-08-04 | 2020-02-20 | BioNTech SE | Binding agents binding to PD-L1 and CD137 and use thereof |
CA3075450A1 (en) * | 2017-09-22 | 2019-03-28 | F. Hoffmann-La Roche Ag | Multivalent mono- or bispecific recombinant antibodies for analytic purpose |
WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
KR20200084006A (ko) | 2017-11-01 | 2020-07-09 | 에프. 호프만-라 로슈 아게 | 표적화된 ox40 작용제를 사용하는 병용 요법 |
WO2019086500A2 (en) * | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Bispecific 2+1 contorsbodies |
JP7312168B2 (ja) * | 2017-11-13 | 2023-07-20 | クレッシェンド、バイオロジックス、リミテッド | Cd137に結合するシングルドメイン抗体 |
EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
EP3818082A1 (en) * | 2018-07-04 | 2021-05-12 | F. Hoffmann-La Roche AG | Novel bispecific agonistic 4-1bb antigen binding molecules |
CN112789294A (zh) * | 2018-07-24 | 2021-05-11 | 印希比股份有限公司 | 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法 |
AR114732A1 (es) | 2018-09-18 | 2020-10-07 | Hoffmann La Roche | Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco |
UA126188C2 (uk) * | 2018-10-01 | 2022-08-25 | Ф. Хоффманн-Ля Рош Аг | Біспецифічна антигензв'язувальна молекула, яка містить домен зв'язування з fap та домен зв'язування з сd40 |
CN112654641A (zh) * | 2018-10-01 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 具有与cd40的三价结合的双特异性抗原结合分子 |
MX2021005594A (es) | 2018-11-13 | 2021-10-22 | Compass Therapeutics Llc | Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos. |
US20220002423A1 (en) * | 2018-11-15 | 2022-01-06 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
CR20210326A (es) | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor |
JP2022537202A (ja) * | 2019-06-19 | 2022-08-24 | エフ.ホフマン-ラ ロシュ アーゲー | 所定の構成の複数の発現カセットの標的指向性組込みによって多価二重特異性抗体発現細胞を作製するための方法 |
MX2021015648A (es) | 2019-06-19 | 2022-02-03 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida. |
CN110452294B (zh) * | 2019-08-06 | 2020-08-07 | 复旦大学 | 五种铰链区及其嵌合抗原受体和免疫细胞 |
AR121706A1 (es) * | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
WO2021225159A1 (ja) * | 2020-05-08 | 2021-11-11 | 国立大学法人三重大学 | Gitr結合性分子 |
BR112022021447A2 (pt) * | 2020-05-19 | 2022-12-13 | Boehringer Ingelheim Int | Moléculas de ligação para o tratamento de câncer |
WO2022074628A1 (en) * | 2020-10-08 | 2022-04-14 | The Governing Council Of The University Of Toronto | Multivalent coronavirus binding molecules and uses thereof |
EP4232470A1 (en) * | 2020-10-23 | 2023-08-30 | Atreca, Inc. | Antibodies to coronavirus sars-cov-2 |
AR128031A1 (es) * | 2021-12-20 | 2024-03-20 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
ATE303445T1 (de) | 1999-10-04 | 2005-09-15 | Medicago Inc | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
CN101289511A (zh) * | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
AU2002339845B2 (en) | 2001-08-03 | 2009-03-26 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
SI1572744T1 (sl) | 2002-12-16 | 2010-09-30 | Genentech Inc | Imunoglobulinske variante in njihove uporabe |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
WO2005003156A1 (en) | 2003-07-04 | 2005-01-13 | Affibody Ab | Polypeptides having binding affinity for her2 |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
TW200531979A (en) | 2003-12-05 | 2005-10-01 | Compound Therapeutics Inc | Inhibitors of type 2 vascular endothelial growth factor receptors |
KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
JP5803913B2 (ja) | 2010-06-29 | 2015-11-04 | コニカミノルタ株式会社 | 超音波診断装置及びプログラム |
CA2808482C (en) | 2010-08-16 | 2021-10-26 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
ES2692268T3 (es) | 2011-03-29 | 2018-12-03 | Roche Glycart Ag | Variantes de Fc de anticuerpo |
BR112014015018A2 (pt) | 2011-12-19 | 2020-10-27 | Synimmune Gmbh | moléculas de anticorpo biespecífico e seu método de produção, bem como composição farmacêutica e molécula de ácido nucleico |
CN104334573A (zh) * | 2012-04-30 | 2015-02-04 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
CN105189557A (zh) * | 2013-03-15 | 2015-12-23 | 默克专利有限公司 | 四价双特异性抗体 |
-
2016
- 2016-09-29 CA CA2992900A patent/CA2992900A1/en not_active Abandoned
- 2016-09-29 RU RU2018116402A patent/RU2018116402A/ru not_active Application Discontinuation
- 2016-09-29 AU AU2016334623A patent/AU2016334623A1/en not_active Abandoned
- 2016-09-29 MX MX2018004157A patent/MX2018004157A/es unknown
- 2016-09-29 CR CR20180171A patent/CR20180171A/es unknown
- 2016-09-29 PE PE2018000513A patent/PE20181349A1/es unknown
- 2016-09-29 WO PCT/EP2016/073198 patent/WO2017060144A1/en active Application Filing
- 2016-09-29 JP JP2018518456A patent/JP7074665B2/ja active Active
- 2016-09-29 MY MYPI2018701351A patent/MY193013A/en unknown
- 2016-09-29 US US15/280,386 patent/US20170247467A1/en not_active Abandoned
- 2016-09-29 BR BR112018002128A patent/BR112018002128A2/pt not_active IP Right Cessation
- 2016-09-29 CN CN201680057648.XA patent/CN108271377B/zh active Active
- 2016-09-29 KR KR1020187012680A patent/KR20180054877A/ko unknown
- 2016-09-29 EP EP16774932.4A patent/EP3359568B1/en active Active
- 2016-09-29 MA MA045640A patent/MA45640A/fr unknown
- 2016-10-05 AR ARP160103048A patent/AR106574A1/es unknown
- 2016-10-06 TW TW105132462A patent/TW201726722A/zh unknown
-
2018
- 2018-01-24 IL IL257128A patent/IL257128A/en unknown
- 2018-01-30 CO CONC2018/0000967A patent/CO2018000967A2/es unknown
- 2018-02-21 CL CL2018000461A patent/CL2018000461A1/es unknown
- 2018-04-06 PH PH12018500766A patent/PH12018500766A1/en unknown
- 2018-12-12 US US16/218,266 patent/US20190211113A1/en not_active Abandoned
-
2019
- 2019-01-04 HK HK19100112.2A patent/HK1257738A1/zh unknown
-
2021
- 2021-06-14 US US17/347,257 patent/US20220073646A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2018116402A3 (es) | 2020-02-27 |
JP7074665B2 (ja) | 2022-05-24 |
KR20180054877A (ko) | 2018-05-24 |
CO2018000967A2 (es) | 2018-04-19 |
MA45640A (fr) | 2019-05-22 |
CN108271377B (zh) | 2021-11-19 |
US20170247467A1 (en) | 2017-08-31 |
RU2018116402A (ru) | 2019-11-07 |
AU2016334623A1 (en) | 2018-02-15 |
WO2017060144A1 (en) | 2017-04-13 |
EP3359568B1 (en) | 2022-03-09 |
CN108271377A (zh) | 2018-07-10 |
CL2018000461A1 (es) | 2018-08-10 |
CA2992900A1 (en) | 2017-04-13 |
TW201726722A (zh) | 2017-08-01 |
IL257128A (en) | 2018-03-29 |
US20220073646A1 (en) | 2022-03-10 |
AR106574A1 (es) | 2018-01-31 |
HK1257738A1 (zh) | 2019-10-25 |
EP3359568A1 (en) | 2018-08-15 |
CR20180171A (es) | 2018-05-03 |
JP2018535665A (ja) | 2018-12-06 |
US20190211113A1 (en) | 2019-07-11 |
MX2018004157A (es) | 2019-04-01 |
PH12018500766A1 (en) | 2018-10-01 |
MY193013A (en) | 2022-09-22 |
BR112018002128A2 (pt) | 2018-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181349A1 (es) | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador | |
PE20180950A1 (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador | |
AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CL2018000378A1 (es) | Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos | |
DOP2018000212A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
ECSP17080639A (es) | Moléculas de unión a lag-3 y métodos de uso de las mismas | |
PE20180330A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso | |
CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
AR109771A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CL2018000358A1 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
EA201891040A1 (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
PE20240111A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
BR112018014760A2 (pt) | anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos | |
UY37758A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
CU20170023A7 (es) | Anticuerpos y receptores de antígeno quiméricos específicos para cd19 | |
CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
AR114284A1 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
AR081750A1 (es) | Anticuerpos anti-cd40 | |
CO2018003852A2 (es) | Proteínas de unión a antigeno que activan el receptor de leptina | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
AR106234A1 (es) | Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador |